It’s January, which is typically when many of us are looking into shedding some pounds. We’ve been hearing a lot about how weight loss drugs are impacting weight loss. Dr. Joseph St. Pierre with Hartford HealthCare Digestive Health Institute joined Good Morning Connecticut at 9 a.

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.

According to that study, those who use GLP-1 dugs, such as Wegovy and Ozempic, cut their grocery spend by about 6% during the first few months after starting their prescription, translating to $416 annually. The impact is even greater in higher-income households earning over $125,000, who reduce their grocery spending by 9%, or $690, annually.

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is typically muscle. The general rule is that three-quarters of what we lose is fat and the rest is lean tissue.

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected to significantly disrupt the pharmaceutical landscape in the country this year.

In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection that promised to transform the lives of those struggling with obesity. The click-baity headlines surrounding Ozempic,

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.